ProMIS Neurosciences

ProMIS Neurosciences ROA

Delisted

The Return on Assets (ROA) of ProMIS Neurosciences (PMN.TO) as of Oct 19, 2026 is -260.84 %. In the previous year, Return on Assets (ROA) was -55.17 % — a change of 372.83% (lower).

ROA

-260.84 %

YoY

372.83%

Last updated:

In 2022, ProMIS Neurosciences's return on assets (ROA) was -260.84 %, a 372.83% increase from the -55.17 % ROA in the previous year.

The ProMIS Neurosciences ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2015
-184.35 CAD
Jan 1, 2016
-355.67 CAD
Jan 1, 2017
-277.42 CAD
Jan 1, 2018
-342.42 CAD
Jan 1, 2019
-357.49 CAD
Jan 1, 2020
-410.14 CAD
Jan 1, 2021
-55.17 CAD
Jan 1, 2022
-260.84 CAD
The ProMIS Neurosciences ROA history
YEARROAYoY
-260.84 %+372.83%
-55.17 %-86.55%
-410.14 %+14.73%
-357.49 %+4.40%
-342.42 %+23.43%
-277.42 %-22.00%
-355.67 %+92.93%
-184.35 %-75.02%
-737.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences Inc is a biopharmaceutical company based in Canada that specializes in the discovery and development of novel therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2004 and has been listed on the Toronto Stock Exchange since 2015. The goal of ProMIS is to develop highly specific therapeutics that specifically target the cellular causes of neurodegenerative diseases and can therefore stop or even reverse the progression of the disease. The company utilizes its proprietary platform technology to identify the unique epitopes on the pathological proteins that are specific to neurodegenerative diseases. ProMIS' business model is based on partnerships with large pharmaceutical companies that are searching for new therapeutics for neurodegenerative diseases. ProMIS works closely with these partners to develop customized therapeutics tailored to each partner's specific needs. The company licenses its technology and products to its partners and receives license and milestone payments when certain development or sales goals are achieved. ProMIS has different divisions to focus on various neurodegenerative diseases, with a focus on Alzheimer's, Parkinson's, and ALS. ProMIS has a comprehensive research and development infrastructure that focuses on the identification, characterization, and optimization of therapeutic antibodies and biomarkers. In terms of products, ProMIS has developed various antibodies that specifically target pathological proteins such as Aß and Tau in Alzheimer's and alpha-synuclein in Parkinson's. These antibodies can selectively recognize and bind to these pathological proteins, allowing them to be broken down and removed from the body. ProMIS works closely with its partners to test these antibodies in clinical trials and eventually bring them to market. In addition to its antibody products, ProMIS has also developed neuromethods that allow researchers to characterize and quantify the functions of proteins in brain cells and in vivo. These methods can be used to test and optimize the effects of antibodies and other therapeutics, making them an important part of ProMIS' development infrastructure. Overall, ProMIS Neurosciences Inc is an innovative biopharmaceutical company that focuses on the development of highly specific therapeutics for neurodegenerative diseases. The company has a comprehensive infrastructure and technology platform that allows it to develop customized products for its partners. With its antibodies and neuromethods, ProMIS has the potential to make a breakthrough in the treatment of neurodegenerative diseases and improve the lives of millions of patients. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

ROA Details

Understanding ProMIS Neurosciences's Return on Assets (ROA)

ProMIS Neurosciences's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing ProMIS Neurosciences's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider ProMIS Neurosciences's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in ProMIS Neurosciences’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about ProMIS Neurosciences stock

Return on Assets (ROA) of ProMIS Neurosciences is -260.84 % in 2022.

Return on Assets (ROA) of ProMIS Neurosciences changed from -55.17 % to -260.84 %, representing a 372.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s ProMIS Neurosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ProMIS Neurosciences

All Key Metrics — ProMIS Neurosciences